Relief from depression sent one writer deep into San Francisco’s booming market for experimental mental health care, where hope, money and uncertainty collide.

The account, drawn from a new memoir by Carly Schwartz and highlighted in reporting from The Guardian, follows a year-long search for something that might ease persistent mental health struggles. That search led her through a string of unconventional treatments, including ketamine, transcranial magnetic stimulation, and even fecal analysis. The details read like a tour of a city where wellness culture and medical ambition often blur into each other.

Reports indicate the deeper story is not just about one person’s treatment choices, but about how far people will go when standard answers fail.

One scene captures the tone of the journey with brutal clarity: Schwartz describes lying blindfolded on the floor of a Bernal Heights bungalow while a shaman injects her with ketamine as music plays and dogs wander over her legs. She writes that even in the moment, she understood the absurdity of what was happening and did not expect it to fix her mental health. That recognition gives the story its edge. This is not a tale of blind faith. It is a record of what desperation can look like when it dresses itself up as innovation.

Key Facts

  • Carly Schwartz recounts a year spent trying experimental approaches to treat depression.
  • The treatments included ketamine, TMS and other unconventional assessments and interventions.
  • The story unfolds in San Francisco, where wellness culture and mental health startups often intersect.
  • Her account suggests the search for relief did not deliver a simple or expected solution.

The story also points to a wider reality. In places like San Francisco, mental health care now sits beside a thriving ecosystem of alternative practitioners, high-cost therapies and personalized optimization claims. For people who feel failed by conventional treatment, that world can seem less fringe than inevitable. Sources suggest the appeal lies in a simple promise: if nothing else has worked, maybe the next thing will.

What happens next matters beyond one memoir. As demand for new depression treatments grows, patients, clinicians and regulators will face sharper questions about evidence, access and harm. Schwartz’s account lands at a moment when experimental care attracts real interest and real money. That makes her story more than a personal misadventure; it becomes a warning about what people may accept when the need for relief outruns the certainty of science.